Avadel Pharmaceuticals PLC (AVDL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Avadel Pharmaceuticals PLC stock (AVDL) is currently trading at $21.64. Avadel Pharmaceuticals PLC PS ratio (Price-to-Sales) is 8.55. Analyst consensus price target for AVDL is $20.71. WallStSmart rates AVDL as Sell.
- AVDL PE ratio analysis and historical PE chart
- AVDL PS ratio (Price-to-Sales) history and trend
- AVDL intrinsic value — DCF, Graham Number, EPV models
- AVDL stock price prediction 2025 2026 2027 2028 2029 2030
- AVDL fair value vs current price
- AVDL insider transactions and insider buying
- Is AVDL undervalued or overvalued?
- Avadel Pharmaceuticals PLC financial analysis — revenue, earnings, cash flow
- AVDL Piotroski F-Score and Altman Z-Score
- AVDL analyst price target and Smart Rating
Avadel Pharmaceuticals
📊 No data available
Try selecting a different time range
Smart Analysis
Avadel Pharmaceuticals PLC (AVDL) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, revenue growth, institutional own.. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Avadel Pharmaceuticals PLC (AVDL) Key Strengths (4)
Growing significantly faster than its price suggests
Revenue surging 54.90% year-over-year
86.80% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Avadel Pharmaceuticals PLC (AVDL) Areas to Watch (5)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Near-zero operating margins, business under pressure
Very expensive at 8.6x annual revenue
Very expensive at 21.6x book value
Supporting Valuation Data
Avadel Pharmaceuticals PLC (AVDL) Detailed Analysis Report
Overall Assessment
This company scores 39/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 4 register as strengths (avg 9.3/10) while 5 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Revenue Growth, Institutional Own.. Valuation metrics including PEG Ratio (0.07) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 54.90%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Operating Margin. Some valuation metrics including Price/Sales (8.55), Price/Book (21.62) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -0.32%, Operating Margin at 2.50%, Profit Margin at -0.11%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -0.32% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 54.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AVDL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AVDL's Price-to-Sales ratio of 8.55x trades at a deep discount to its historical average of 34.8x (23th percentile). The current valuation is 95% below its historical high of 158.9x set in Jul 2015, and 506% above its historical low of 1.41x in Dec 2018.
Compare AVDL with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Avadel Pharmaceuticals PLC (AVDL) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Avadel Pharmaceuticals PLC is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 249M with 55% growth year-over-year. The company is currently unprofitable, posting a -0.1% profit margin.
Key Findings
Revenue growing at 55% YoY, reaching 249M. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
Generating 23M in free cash flow and 23M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -0.1% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Avadel Pharmaceuticals PLC maintain 55%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.63, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Avadel Pharmaceuticals PLC.
Bottom Line
Avadel Pharmaceuticals PLC is a high-conviction growth story with revenue accelerating at 55% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -0.1% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Avadel Pharmaceuticals PLC(AVDL)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Avadel Pharmaceuticals plc is a biopharmaceutical company in the United States. The company is headquartered in Dublin, Ireland.